NCT06976333

Brief Summary

Endometrial cancer (EC) is a leading cancer among women globally. The tumor microenvironment in EC is characterized by complex interactions between cancer cells and immune components. Among these proteins, CD133, WNT-1, and mTOR have emerged as key molecular markers with potential prognostic and therapeutic implications in EC. Understanding the association between these molecular alterations and the immune contexture of EC can provide valuable insights into EC biology and lead to the identification of novel therapeutic targets. In this study, the spatial organization of tumor-infiltrating lymphocytes (TILs) in EC and their correlations with tumor grade, stage, and subcellular CD133, WNT-1, and mTOR expression were investigated. Artificial intelligence-assisted image analysis was performed to quantify TIL metrics, including TIL percentage, grey level co-occurrence matrix (GLCM M1 and M2) parameters, and fractal dimension (FD).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
8 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 8, 2025

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

May 9, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 16, 2025

Completed
Last Updated

May 16, 2025

Status Verified

May 1, 2025

Enrollment Period

5 months

First QC Date

May 9, 2025

Last Update Submit

May 9, 2025

Conditions

Keywords

endometrial cancertumor-infiltrating lymphocytesresponse biomarkersartificial intelligenceimmune microenvironment

Outcome Measures

Primary Outcomes (4)

  • TIL percentage [%]

    TIL percentage is the area occupied by lymphocytes divided by the cancer area, expressed as a percentage \[%\]

    up to 6 months

  • GLCM M1 (×10⁶)

    GLCM is a second-order statistical method for texture feature extraction. Structured images typically contain numerous pixel pairs with co-occurring low- and high-intensity values. After GLCM calculation, different weights were applied to each matrix element to derive two measures: M1 and M2, representing areas with low and high intensities, respectively. Lower M1 and higher M2 values characterize more structured images with distinct TIL patterns. GLCM M1 values are scaled and expressed in millions (×10⁶), with lower values indicating more structured TIL patterns.

    up to 6 months

  • FD

    FD provides a statistical index of pattern complexity in geometric structures. Higher FD values thus indicate more structured and complex TIL distribution patterns

    up to 6 months

  • GLCM M2 (×10³)

    GLCM is a second-order statistical method for texture feature extraction. Structured images typically contain numerous pixel pairs with co-occurring low- and high-intensity values. After GLCM calculation, different weights were applied to each matrix element to derive two measures: M1 and M2, representing areas with low and high intensities, respectively. Lower M1 and higher M2 values characterize more structured images with distinct TIL patterns. GLCM M2 values are scaled and expressed in thousands (×10³), with higher values indicating increased TIL clustering.

    up to 6 months

Study Arms (2)

Low-grade Endometrial Cancer

Histological grade G1 and G2

Diagnostic Test: Tumor-infliltrating lymphocyte (TIL) percentageDiagnostic Test: Grey level co-occurrence matrix (GLCM)Diagnostic Test: Fractal dimension (FD)

High-grade Endometrial Cancer

Histological grade G3

Diagnostic Test: Tumor-infliltrating lymphocyte (TIL) percentageDiagnostic Test: Grey level co-occurrence matrix (GLCM)Diagnostic Test: Fractal dimension (FD)

Interventions

TIL percentage was calculated as the area occupied by lymphocytes divided by the cancer area, expressed as a percentage \[%\]

High-grade Endometrial CancerLow-grade Endometrial Cancer

The GLCM is a second-order statistical method for texture feature extraction. Structured images typically contain numerous pixel pairs with co-occurring low- and high-intensity values. After GLCM calculation, different weights were applied to each matrix element to derive two measures: M1 and M2, representing areas with low and high intensities, respectively. Lower M1 and higher M2 values characterized more structured images with distinct TIL patterns.

High-grade Endometrial CancerLow-grade Endometrial Cancer
Fractal dimension (FD)DIAGNOSTIC_TEST

Quantification of the complexity of TIL

High-grade Endometrial CancerLow-grade Endometrial Cancer

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Archival properly stored formalin-fixed paraffin-embedded tissue blocks from endometrial cancer tissue of women age at leat 18.

You may qualify if:

  • confirmed diagnosis of EC
  • adequate quality of archival material
  • absence of prior neoadjuvant treatment
  • complete medical documentation

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jagiellonian University

Krakow, Poland

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

archival formalin-fixed paraffin-embedded tissue blocks

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Milosz Pietrus, PhD

    Jagiellonian University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 9, 2025

First Posted

May 16, 2025

Study Start

December 1, 2024

Primary Completion

April 30, 2025

Study Completion

May 8, 2025

Last Updated

May 16, 2025

Record last verified: 2025-05

Locations